English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Historically, refractory/relapsed (r/r) acute B-lymphoblastic leukemia (ALL) in adults has a dismal prognosis, with less than 10% of patients being long-term survivors, which is only achievable through a bone marrow (BM) transplantation.1 The emergence of targeted therapies for ALL has shown that is possible to reach deep remissions even in these patients, achieving negative minimal residual disease (MRD) status, which is paramount for cure.2 Blinatumomab is a bispecific T-cell engager which binds human CD19 (B lymphoblasts) and CD3 (T-cell), stimulating the formation of a cytolytic synapse and cell lysis.2 Inotuzumab Ozogamicin (IO) is an anti-CD22 monoclonal antibody which delivers a potent cytotoxic agent (calicheamicin) into the cell, inducing apoptosis.3

Primary refractory B-cell lymphoblastic leukemia with extramedullary disease – a distinctive response to blinatumomab and inotuzumab ozogamicin